Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

This study has been completed.

Study NCT00006364 Information provided by National Cancer Institute (NCI)

First Received: October 4, 2000 Last Updated: June 4, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

Publications:

Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer. 2007 Jan 15;109(2):248-55.

Quintas-Cardama A, Cortes J, Verstovsek S, et al.: Subcutaneous (SC) homoharringtonine (HHT) for patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) after imatinib mesylate failure. [Abstract] Blood 106 (11): A-4839, 2005 .